Beyond clinical characteristics [4], molecular features associated with DLBCL prognosis include cell-of-origin (COO) [5, 6] and MYC, BCL2, or BCL6 translocation status, or MYC “double hits (DH)” [7–9], with DH-DLBCL now considered as a distinct entity, High Grade B Cell Lymphoma (HGBCL) [10]. This evidence concerns the gene MYC and diffuse large B-cell lymphoma.